Literature DB >> 24770803

Molecular dynamics simulations and principal component analysis on human laforin mutation W32G and W32G/K87A.

P S Srikumar1, K Rohini, Perumbilavil Kaithamanakallam Rajesh.   

Abstract

Mutations in human laforin lead to an autosomal neurodegenerative disorder Lafora disease. In N-terminal carbohydrate binding domain of laforin, two mutations W32G and K87A are reported as highly disease causing laforin mutants. Experimental studies reported that mutations are responsible for the abolishment of glycogen binding which is a critical function of laforin. Our current computational study focused on the role of conformational changes in human laforin structure due to existing single mutation W32G and prepared double mutation W32G/K87A related to loss of glycogen binding. We performed 10 ns molecular dynamics (MD) simulation studies in the Gromacs package for both mutations and analyzed the trajectories. From the results, the global properties like root mean square deviation, root mean square fluctuation, radius of gyration, solvent accessible surface area and hydrogen bonds showed structural changes in atomic level observed in W32G and W32G/K87A laforin mutants. The conformational change induced by mutants influenced the loss of the overall stability of the native laforin. Moreover, the change in overall motion of protein was analyzed by principal component analysis and results showed protein clusters expanded more than native and also change in direction in case of double mutant in conformational space. Overall, our report provides theoretical information on loss of structure-function relationship due to flexible nature of laforin mutants. In conclusion, comparative MD simulation studies support the experimental data on W32G and W32G/K87A related to the lafora disease mechanism on glycogen binding.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24770803     DOI: 10.1007/s10930-014-9561-2

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  14 in total

1.  SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling.

Authors:  N Guex; M C Peitsch
Journal:  Electrophoresis       Date:  1997-12       Impact factor: 3.535

2.  Myoclonic epilepsy with lafora bodies. Some ultrastructural, histochemical, and biochemical aspects.

Authors:  P Gambetti; S Di Mauro; L Hirt; R P Blume
Journal:  Arch Neurol       Date:  1971-12

3.  Lafora progressive Myoclonus Epilepsy mutation database-EPM2A and NHLRC1 (EPM2B) genes.

Authors:  Leonarda Ianzano; Junjun Zhang; Elayne M Chan; Xiao-Chu Zhao; Hannes Lohi; Stephen W Scherer; Berge A Minassian
Journal:  Hum Mutat       Date:  2005-10       Impact factor: 4.878

4.  Essential dynamics of proteins.

Authors:  A Amadei; A B Linssen; H J Berendsen
Journal:  Proteins       Date:  1993-12

5.  A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen.

Authors:  Jianyong Wang; Jeanne A Stuckey; Matthew J Wishart; Jack E Dixon
Journal:  J Biol Chem       Date:  2001-12-05       Impact factor: 5.157

6.  Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes.

Authors:  S Ganesh; K L Agarwala; K Ueda; T Akagi; K Shoda; T Usui; T Hashikawa; H Osada; A V Delgado-Escueta; K Yamakawa
Journal:  Hum Mol Genet       Date:  2000-09-22       Impact factor: 6.150

7.  Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions.

Authors:  P Gómez-Garre; Y Sanz; S R Rodríguez De Córdoba; J M Serratosa
Journal:  Eur J Hum Genet       Date:  2000-12       Impact factor: 4.246

8.  Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo.

Authors:  Vincent S Tagliabracci; Julie Turnbull; Wei Wang; Jean-Marie Girard; Xiaochu Zhao; Alexander V Skurat; Antonio V Delgado-Escueta; Berge A Minassian; Anna A Depaoli-Roach; Peter J Roach
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-26       Impact factor: 11.205

9.  Typical progression of myoclonic epilepsy of the Lafora type: a case report.

Authors:  Pasquale Striano; Federico Zara; Julie Turnbull; Jean-Marie Girard; Cameron A Ackerley; Mariarosaria Cervasio; Gaetano De Rosa; Maria Laura Del Basso-De Caro; Salvatore Striano; Berge A Minassian
Journal:  Nat Clin Pract Neurol       Date:  2008-02

Review 10.  Lafora disease: insights into neurodegeneration from plant metabolism.

Authors:  Matthew S Gentry; Jack E Dixon; Carolyn A Worby
Journal:  Trends Biochem Sci       Date:  2009-10-07       Impact factor: 13.807

View more
  11 in total

1.  A molecular dynamics approach to explore the structural characterization of cataract causing mutation R58H on human γD crystallin.

Authors:  Rohini Karunakaran; P S Srikumar
Journal:  Mol Cell Biochem       Date:  2018-03-12       Impact factor: 3.396

2.  Metal binding mediated conformational change of XPA protein:a potential cytotoxic mechanism of nickel in the nucleotide excision repair.

Authors:  Jianping Hu; Ziheng Hu; Yan Zhang; Xiaojun Gou; Ying Mu; Lirong Wang; Xiang-Qun Xie
Journal:  J Mol Model       Date:  2016-06-16       Impact factor: 1.810

3.  Molecular Dynamics Simulation and Essential Dynamics of Deleterious Proline 12 Alanine Single-Nucleotide Polymorphism in PPARγ2 Associated with Type 2 Diabetes, Cardiovascular Disease, and Nonalcoholic Fatty Liver Disease.

Authors:  Somayye Taghvaei; Leila Saremi
Journal:  PPAR Res       Date:  2022-05-02       Impact factor: 4.385

4.  The unique evolution of the carbohydrate-binding module CBM20 in laforin.

Authors:  Andrea Kuchtová; Matthew S Gentry; Štefan Janeček
Journal:  FEBS Lett       Date:  2018-02-15       Impact factor: 4.124

5.  Conformational transition pathway in the inhibitor binding process of human monoacylglycerol lipase.

Authors:  Huayou Chen; Rui Tian; Zhong Ni; Zhongge Zhang; Hongzhang Chen; Qi Guo; Milton H Saier; Ake Vastermark
Journal:  Protein J       Date:  2014-12       Impact factor: 2.371

6.  Calendulaglycoside A showing potential activity against SARS-CoV-2 main protease: Molecular docking, molecular dynamics, and SAR studies.

Authors:  Ahmed A Zaki; Ahmed Ashour; Sameh S Elhady; Khaled M Darwish; Ahmed A Al-Karmalawy
Journal:  J Tradit Complement Med       Date:  2021-05-17

7.  Investigating the structure-activity relationship of marine natural polyketides as promising SARS-CoV-2 main protease inhibitors.

Authors:  Amr El-Demerdash; Ahmed A Al-Karmalawy; Tarek Mohamed Abdel-Aziz; Sameh S Elhady; Khaled M Darwish; Ahmed H E Hassan
Journal:  RSC Adv       Date:  2021-09-22       Impact factor: 4.036

8.  Alanine mutation of the catalytic sites of Pantothenate Synthetase causes distinct conformational changes in the ATP binding region.

Authors:  Bharati Pandey; Sonam Grover; Sukriti Goyal; Anchala Kumari; Aditi Singh; Salma Jamal; Jagdeep Kaur; Abhinav Grover
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

9.  Molecular Docking and Dynamics Simulation Study of Hyrtios erectus Isolated Scalarane Sesterterpenes as Potential SARS-CoV-2 Dual Target Inhibitors.

Authors:  Sameh S Elhady; Reda F A Abdelhameed; Rania T Malatani; Abdulrahman M Alahdal; Hanin A Bogari; Ahmad J Almalki; Khadijah A Mohammad; Safwat A Ahmed; Amgad I M Khedr; Khaled M Darwish
Journal:  Biology (Basel)       Date:  2021-05-01

10.  Using Chou's 5-steps rule to study pharmacophore-based virtual screening of SARS-CoV-2 Mpro inhibitors.

Authors:  Hemlata Pundir; Tanuja Joshi; Tushar Joshi; Priyanka Sharma; Shalini Mathpal; Subhash Chandra; Sushma Tamta
Journal:  Mol Divers       Date:  2020-10-20       Impact factor: 3.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.